Group 1 - Shanghai Municipal Government issued measures to support enterprises in enhancing basic research and high-quality development [4][5] - Hainan Provincial Government released a three-year action plan to accelerate the construction of a modern industrial system with distinctive advantages [4] - Shanghai Science and Technology Committee introduced management measures for the "Explorer Program" to encourage enterprises to invest in basic research [4] Group 2 - AI agent concept gained traction with several companies experiencing significant stock price increases following the certification of an AI customer service agent [9] - The global first organic solvent testing standard for footwear was officially released, addressing a critical global issue [6] - The electric vehicle industry is witnessing advancements with the announcement of the world's first mass-produced semi-solid battery vehicle [14][15] Group 3 - The innovative drug sector remains active, with several companies experiencing stock price surges due to strategic partnerships and clinical trial advancements [12][13] - Public fund issuance continues to rise, with 36 new funds launched this week, marking a 5.88% increase from the previous week [26] - Foreign investment in A-shares is increasing, with four stocks having over 24% of their shares held by foreign investors [27]

药品名称：VUM02注射液 剂型：注射剂 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600645 证券简称：中源协和 公告编号：2025-032 中源协和细胞基因工程股份有限公司 关于全资子公司药品临床试验申请 取得受理通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 中源协和细胞基因工程股份有限公司（以下简称"公司"）全资子公司武汉光谷中源药业有限公司于2025 年8月1日取得国家药品监督管理局药品审评中心（CDE）签发的关于VUM02注射液临床试验申请《受 理通知书》，受理号为CXSL2500651。现对有关信息公告如下： 一、药品基本信息 二、药品研发等情况 VUM02注射液（人脐带源间充质基质细胞注射液）是我司自主研发的冷冻保存型细胞制剂，是由经筛 选的健康新生儿脐带组织通过体外分离、扩增、收获、冻存后制备的人脐带源间充质基质细胞（UC- MSC）新药，临床拟用适应症增加肺炎后肺纤维化的治疗。截至本公告日，全球尚未有用于治疗肺炎 后肺纤维化的同类细胞药物上市，研发进展最快的同类药物处于研发 ...

（编辑 任世碧） 证券日报网讯 8月4日晚间，中源协和发布公告称，公司全资子公司武汉光谷中源药业有限公司于2025 年8月1日取得国家药品监督管理局药品审评中心（CDE）签发的关于VUM02注射液临床试验申请《受 理通知书》。 ...

Group 1 - Weihai Guangtai reported a net profit of 83.32 million yuan for the first half of 2025, a year-on-year decrease of 22.41%, while total revenue reached 1.425 billion yuan, an increase of 10.91% [1] - Haowei Group expects a net profit increase of 39.43% to 49.67% for the first half of 2025, estimating a profit range of 1.906 billion to 2.046 billion yuan [1] - Tengda Construction won a bid for a project worth 118 million yuan, with a construction period of 500 calendar days [1] Group 2 - Shanda Power plans to use up to 520 million yuan of idle raised funds for cash management, investing in safe and liquid products with a term not exceeding 12 months [3] - Rundu Co., Ltd. received approval for the listing application of its chemical raw material drug, which is suitable for surgical treatment in adults and children over one month old [4] - Zhongyuan Qihua's subsidiary's clinical trial application for a drug aimed at treating pulmonary fibrosis has been accepted [4] Group 3 - Shanghai Xiba plans to establish a joint venture with Yuyuan Rare Earth, focusing on advanced materials for lithium-ion solid-state batteries, with a registered capital of 200 million yuan [6] - Aorite's senior management plans to reduce their holdings by up to 62,500 shares, accounting for 0.02% of the company's total equity [7] - Yipin Hong's subsidiary's clinical trial application for a new oral drug for endometriosis has been accepted [8] Group 4 - Haya Pharmaceutical plans to lease idle assets covering 22,671.39 square meters for a period of 10 years [9] - Southern Precision Engineering applied for a credit limit of 50 million yuan from a bank for operational purposes [11] - Jindawei's subsidiary established a joint venture with a registered capital of 5 million yuan, focusing on the sale of food additives and health products [12] Group 5 - Gaode Infrared signed a product order contract worth 307 million yuan, expected to account for 11.46% of the company's audited revenue for 2024 [13] - Xichang Electric will implement a low valley electricity price policy starting September 1, 2025, which is expected to reduce net profit by approximately 5.55 million yuan [14] - Huyou Pharmaceutical's first subject has been dosed in a Phase I clinical trial for a drug targeting advanced solid tumors [16] Group 6 - Chuanheng Co., Ltd. received a patent for a dust removal system in mining operations [17] - Spring Wind Power's application for issuing convertible bonds has been accepted by the Shanghai Stock Exchange [18] - Liuyao Group plans to repurchase shares worth between 100 million and 200 million yuan [19] Group 7 - Baiyun Electric has obtained a commitment letter for a stock repurchase loan of up to 18 million yuan [20] - Tonghe Pharmaceutical received a patent for a method of preparing an intermediate for a migraine treatment drug [21] - Tainkang's subsidiary's Phase II clinical trial for a drug for vitiligo has shown significant efficacy and safety [23] Group 8 - Yuhua Tian's secretary and deputy general manager resigned for personal reasons [24] - Heizhima's controlling shareholder is planning a change in control, leading to a temporary suspension of stock trading [25] - Keda Li's subsidiary completed a capital increase, raising its registered capital to 700 million yuan [26] Group 9 - Fangda Special Steel's shareholder plans to reduce holdings by up to 1% of the company's shares [28] - ST Pava's director is under investigation for alleged embezzlement, but the company's operations remain normal [29] - Jiachuan Video's controlling shareholder is planning a change in control, resulting in a temporary stock suspension [32] Group 10 - Danhua Technology will change its stock name to Jinmei Technology starting August 7, 2025, due to a relocation of its registered office [33] - Morning Wind Technology's shareholder plans to reduce holdings by up to 1% of the company's shares [34] - Leshan Electric will adjust residential gas prices starting September 1, 2025, which is expected to increase gross profit by approximately 2.7 million yuan [35] Group 11 - SAIC Motor reported a total vehicle sales of 337,500 units in July 2025, a year-on-year increase of 34.22%, with significant growth in new energy vehicle sales [36] - LIGONG Navigation's shareholders plan to reduce holdings by up to 3% of the company's shares [37] - United Imaging's employee stock ownership platform plans to reduce holdings by up to 1.62% of the company's shares [38] Group 12 - Beiqi Blue Valley's subsidiary reported a 6.38% decline in sales in July 2025 [39] - Watson Bio's clinical research application for an mRNA vaccine has been accepted [40]

格隆汇8月4日丨中源协和(600645.SH)公布，全资子公司武汉光谷中源药业有限公司于2025年8月1日取 得国家药品监督管理局药品审评中心（CDE）签发的关于VUM02注射液临床试验申请《受理通知 书》，受理号为CXSL2500651。VUM02注射液（人脐带源间充质基质细胞注射液）是我司自主研发的 冷冻保存型细胞制剂，是由经筛选的健康新生儿脐带组织通过体外分离、扩增、收获、冻存后制备的人 脐带源间充质基质细胞（UC-MSC）新药，临床拟用适应症增加肺炎后肺纤维化的治疗。 ...

VUM02注射液(人脐带源间充质基质细胞注射液)是公司自主研发的冷冻保存型细胞制剂，是由经筛选的 健康新生儿脐带组织通过体外分离、扩增、收获、冻存后制备的人脐带源间充质基质细胞(UC-MSC)新 药，临床拟用适应症增加肺炎后肺纤维化的治疗。截至公告日，全球尚未有用于治疗肺炎后肺纤维化的 同类细胞药物上市，研发进展最快的同类药物处于研发早期阶段。该适应症申报系依托本品前期已获得 的新冠肺炎临床研究和特发性肺纤维化I期临床试验研究数据作为支撑。 中源协和（600645）(600645.SH)发布公告，公司全资子公司武汉光谷中源药业有限公司于2025年8月1 日取得国家药品监督管理局药品审评中心(CDE)签发的关于VUM02注射液临床试验申请《受理通知 书》，受理号为CXSL2500651。 ...

VUM02注射液(人脐带源间充质基质细胞注射液)是公司自主研发的冷冻保存型细胞制剂，是由经筛选的 健康新生儿脐带组织通过体外分离、扩增、收获、冻存后制备的人脐带源间充质基质细胞(UC-MSC)新 药，临床拟用适应症增加肺炎后肺纤维化的治疗。截至公告日，全球尚未有用于治疗肺炎后肺纤维化的 同类细胞药物上市，研发进展最快的同类药物处于研发早期阶段。该适应症申报系依托本品前期已获得 的新冠肺炎临床研究和特发性肺纤维化I期临床试验研究数据作为支撑。 智通财经APP讯，中源协和(600645.SH)发布公告，公司全资子公司武汉光谷中源药业有限公司于2025 年8月1日取得国家药品监督管理局药品审评中心(CDE)签发的关于VUM02注射液临床试验申请《受理通 知书》，受理号为CXSL2500651。 ...

每经AI快讯，8月4日，中源协和(600645.SH)公告称，公司全资子公司武汉光谷中源药业有限公司于 2025年8月1日取得国家药品监督管理局药品审评中心签发的关于VUM02注射液临床试验申请《受理通 知书》。VUM02注射液为中源协和自主研发的冷冻保存型细胞制剂，临床拟用适应症增加肺炎后肺纤 维化的治疗。 （文章来源：每日经济新闻） ...

中源协和（600645）公告，全资子公司武汉光谷中源协和细胞基因工程股份公司收到国家药品监督管理 局药品审评中心出具的《受理通知书》，其产品VUM02注射液的临床试验申请已获受理。VUM02注射 液拟用于治疗特发性肺纤维化(IPF)引起的下呼吸道疾病。 ...